Axsome Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, received Fast Track designation from the U.S. Food and Drug Administration for AXS-05 for treatment resistant depression . AXS-05 is currently being evaluated in the STRIDE-1 study, a Phase 3, randomized, double-blind, active-controlled trial to assess the efficacy and safety of AXS-05 in the treatment of TRD.
Donald Trump PRAYS with Martin Luther King's son: President-elect makes peace move with MLK III- who issues call to 'bring America together' after Trump's spat with civil rights icon John Lewis Are YOU being plagued by a hacking cough this winter? Leading expert reveals the best cold treatments available on your local High Street A cough related to a cold occurs when the virus hijacks the cough reflex . The virus uses this defence mechanism to spread itself further: it makes the nerves and cough receptors in the upper respiratory passages hypersensitive .